MedTrace Logo

Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

NCT07271043 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-30

No results posted yet for this study

Summary

A randomized clinical study to assess the efficacy of a high-protein diabetes specific formula (HPDSF) on lean muscle mass in overweight and obese patients with type 2 diabetes who are initiating treatment with incretin-mimetic drugs.

Conditions

Interventions

DIETARY_SUPPLEMENT

protein supplement

HP-DSF shakes (Protality Base or Ensure Max Protein by Abbott Nutrition)

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Joslin Diabetes Center

    lead OTHER

Principal Investigators

  • Osama Hamdy, MD, PhD · Joslin Diabetes Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-11-01
Completion
2026-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07271043 on ClinicalTrials.gov